ASCRS 2024: International data are forthcoming in corneal endothelial disease treatment

At this year's ASCRS meeting in Boston, Massachusetts, Ophthalmology Times Europe caught up with Eris Jordan, OD. She talked about the big plans the Boston-based startup has for the year ahead. Watch the full video to find out what's in store for the company and its novel cell therapy in Japan, Canada and the United States in 2024.

Video Transcript

Editor's note: The below transcript has been lightly edited for clarity.

Eris Jordan, OD:

Hi, I'm Eris Jordan, Global Vice President of Clinical and Medical Affairs at Aurion Biotech. We are here at the 2024 ASCRS in our hometown of Boston, Massachusetts. Aurion has been busy at work. And it's been an incredible year so far, with several milestones that are coming our way, one of which is soon fully enrolling our first North American trial, which happily included Canadian sites as well. As we know, there's a great demand there of patients that are waiting in the queue to be treated [for] corneal endothelial disease. So we are very proud to say that we've enrolled this trial quickly, and very humbled with the amount of support and enthusiasm that we've received from our principal investigators, from our participating sites, and just the KOLs in this space. We continue to progress also with our endeavours internationally as we plan to launch our program commercially in Japan later this year. Our top line data for the first US and Canadian trial is expected later in this year, or Q1 of next year. And we're incredibly thrilled to just inch this progress a bit closer to the patients that need it, and look forward to giving you updates as we have them in future conferences. So, we're thankful to continue to report to you guys on Aurion's important work.